Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)

CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)

This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-19-006-L01-P).

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Physician Assistants (AAPA)

Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.

Objectives

At the conclusion of this application-based activity, participants will be able to:

  • Analyze the changing paradigm in clinical approaches to management of B-cell malignancies with BTK therapy and the implications for patient care.
  • Examine key issues in therapy selection, including appropriate sequencing and combination of agents in a range of clinical scenarios based on individual patient factors, as well as disease and treatment status.
  • Identify strategies to successfully incorporate novel therapies for B-cell malignancies, including the growing range of targeted therapies, into clinical practice.

Target Audience

Practitioners involved in the care of patients with B-cell malignancies including hematologists, oncologists, hem/onc residents/fellows, heme specialty NPs, nurses, nurse navigators, PAs, and pharmacists.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity. 

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
John N. Allan, MD–has disclosed that he is a consultant for Abbvie, Genentech, Pharmacyclics, and Verastem.
Michael Wang, MD– has disclosed that he is a consultant for AstraZeneca, AxImmune, Celgene, Janssen, MoreHealth and Pulse Biosciences; receives grant/research support from Janssen; AstraZeneca, BeiGene, Celgene, Kite Pharma; Juno Therapeutics and Pharmacyclics. He is also a major stockholder in MoreHealth. 

Presenters:
John N. Allan, MD–has disclosed that he is a consultant for Abbvie, Genentech, Pharmacyclics, and Verastem.
Danielle M. Brander, MD–has disclosed that she is a consultant for Abbvie, Genentech, Pharmacyclics, T6 Therapeutics, and Teva. She receives other financial/material support from the Novartis.
Nina Wagner-Johnston, MD–has disclosed that she is a consultant for ADC Therapeutics, Janssen, and Juno.
Loretta J. Nastoupil, MD–has disclosed that she is a consultant for Celgene, Genentech, Gilead, and Merck.
Stephen E. Spurgeon, MD–has disclosed that he is a consultant for Gilead and Pharmacyclics. He also receives grant/research support Acerta, AstraZeneca, Bristol-Myers Squibb, and Genentech.